Drug Trial Radar · NCT01743651
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
Nov 2012
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- RVL Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Osmotica Pharmaceutical US LLC
- First posted
- Dec 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity. Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks.
Conditions
- Spasticity
- Multiple Sclerosis
Interventions
arbaclofenDrug
40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
baclofenDrug
80 mg/day as 20 mg baclofen administered orally 4 times per day
PlaceboDrug
arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb.Time frame: Change in baseline from Visit 1 through Visit 9 (120 days) or end of treatment
- Clinical Global Impression of Change (CGIC) through end of treatmentTime frame: Visit 9 (120 days) or end of study
Locations
48 sites in 3 countries. Site status is shown where the registry gives one.
Osmotica Study Site-138
Cullman, Alabama
Osmotica Site-143
Long Beach, California
Osmotica Study Site-123
Aurora, Colorado
Osmotica Study Site-110
Bradenton, Florida
Osmotica Study Site-142
Maitland, Florida
Osmotica Study Site-119
Ormond Beach, Florida
Osmotica Study Site-120
Pompano Beach, Florida
Osmotica Study Site-109
Tampa, Florida
Osmotica Study Site-126
Northbrook, Illinois
Osmotica Study Site-108
Fort Wayne, Indiana
Osmotica Study Site-116
Lenexa, Kansas
Osmotica Study Site-124
Baltimore, Maryland
Osmotica Study Site-136
Springfield, Massachusetts
Osmotica Study Site-101
Ann Arbor, Michigan
Osmotica Study Site-115
Johnson City, New York
Osmotica Study Site-113
New York, New York
Osmotica Study Site-141
New York, New York
Osmotica Study Site-125
New York, New York
Osmotica Study Site-106
Charlotte, North Carolina
Osmotica Study Site-131
Cincinnati, Ohio
Osmotica Study Site-127
Pittsburgh, Pennsylvania
Osmotica Study Site-112
San Antonio, Texas
Osmotica Study Site-133
Salt Lake City, Utah
Osmotica Study Site-129
Seattle, Washington
Osmotica SIte-144
Tacoma, Washington
Osmotica Site-511
Krasnoyarsk, Russia
Osmotica Study Site-508
Krasnoyarsk, Russia
Osmotica Study Site-510
Krasnoyarsk, Russia
Osmotica Study Site-501
Moscow, Russia
Osmotica Study Site-502
Moscow, Russia
Osmotica Study Site-503
Saint Petersburg, Russia
Osmotica Study Site-505
Saint Petersburg, Russia
Osmotica Study Site-507
Saint Petersburg, Russia
Osmotica Study Site-506
Sestroretsk, Russia
Osmotica Study Site-509
Pyatigorsk, Stavropol Kray, Russia
Osmotica Study Site-510
Tonnel’nyy, Stavropol Kray, Russia
Osmotica Study Site 614
Chernihiv, Ukraine
Osmotica Study Site-602
Dnipropetrovsk, Ukraine
Osmotica Study Site-603
Dnipropetrovsk, Ukraine
Osmotica Study Site-609
Dnipropetrovsk, Ukraine
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.